Evaluating innovations in CV care

Today’s cardiovascular innovations have more complex value propositions than the innovations we evaluated in the past: they cater to niche patient populations, require a program to attract and manage patients, and often derive their value more from cost avoidance than revenue generation. Evaluating CV innovations is similarly more complex today, especially because CV leaders must prioritize cost control in addition to revenue growth.

But while our innovations and our priorities have both changed, our method of evaluating new technologies has not. CV leaders must adapt their evaluation model to account for the range of value propositions new technologies offer—with cost control placed front and center.

To get started, read below why our old model is outdated and how to evaluate investing in CV innovation going forward. Then, jump to explore resources on the most pressing CV innovations.

Log in to access this.

Full access to this content is reserved for Cardiovascular Roundtable members.
Log in or learn how membership works.